Comparison
BPC-157 vs. Dulaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
923950-08-7
Molecular weight
1419.5 g/mol
59670 g/mol
Half-life
4 h
110 h
Sequence
GEPPPGKPADDAGLVGLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
5
Effects recorded
4
3
Open conflicts
2
0
Documented adverse events
2
2